Results 101 to 110 of about 18,160 (234)
Is Paul A. Weiss' and Ludwig von Bertalanffy's system thinking still valid today? [PDF]
, 2007 Manfred Drack, Wilfried Apfalter
openalex +1 more source
Molecular Oncology, EarlyView.A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Exploring Systems Thinking Typologies and Paradigms
SAGE OpenToday’s agriculture, food, and natural resources (AFNR) sectors face many wicked problems like climate change. Addressing these complex problems will require people to have both social and technical knowledge.
Katrina R. Alford +4 more
doaj +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
PERSIST: a pre–post study to assess an educational methodology to enhance youth climate literacy and systems thinking ability [PDF]
Doris Zjalic +4 more
openalex +1 more source
Prairie Protector: student development of systems thinking habits in the context of agroecosystems [PDF]
, 2023 Erin Ingram, Jenny Keshwani
openalex +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells
Molecular Oncology, EarlyView.Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son +13 more
wiley +1 more source